Two Sigma Securities’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Two Sigma Securities’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-11,466	Closed	-$4K	–	871
2016 Q2	$4K	Sell	11,466 -10,345	-47%	-$3.94K	﹤0.01%	414
2016 Q1	$8K	Buy	+21,811	New	+$8.98K	0.01%	269
2015 Q1	–	Sell	-12,490	Closed	-$10K	–	371
2014 Q4	$10K	Buy	+12,490	New	+$11.4K	0.01%	241

Other funds holding PVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Two Sigma Securities's PVCT Position: Q3 2016 in Review

Two Sigma Securities sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q3 2016, closing a stake of 11,466 shares — an estimated $4K sold.

Two Sigma Securities first reported a position in PVCT in Q4 2014 and held it in 3 quarters. The position peaked at $10K in Q4 2014. 41 funds tracked by Wall St. Rank hold PVCT as of Q3 2016.

Two Sigma Securities reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q3 2016 after selling out during the quarter.
Two Sigma Securities sold 11,466 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q3 2016, an estimated $4K.
Two Sigma Securities first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2014 and held it in 3 quarters.
Two Sigma Securities's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $10K in Q4 2014.
41 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q3 2016.

Based on Two Sigma Securities's 13F filing for Q3 2016, filed 14 Nov 2016.